about
In Vivo Delivery Systems for Therapeutic Genome EditingNew and emerging targeted therapies for cystic fibrosisAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraNuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome EditingInduced Pluripotency and Gene Editing in Disease Modelling: Perspectives and ChallengesApplications of CRISPR-Cas systems in neuroscienceEnabling functional genomics with genome engineeringStrategies for precision modulation of gene expression by epigenome editing: an overviewThe complexity of epigenetic diseasesThe New State of the Art: Cas9 for Gene Activation and RepressionProgress and Prospects of Anti-HBV Gene Therapy DevelopmentOff-target Effects in CRISPR/Cas9-mediated Genome EngineeringGenome-editing technologies for gene correction of hemophiliaGenome editing: the road of CRISPR/Cas9 from bench to clinicBiopharmaceuticals from microorganisms: from production to purificationApplications of CRISPR/Cas9 for Gene Editing in Hereditary Movement DisordersTranslation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision MedicineHuman induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypesCompanion animals: Translational scientist's new best friendsTherapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivoThe notorious R.N.A. in the spotlight - drug or target for the treatment of diseaseACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamicsImproving the DNA specificity and applicability of base editing through protein engineering and protein delivery.RNA-guided transcriptional activation via CRISPR/dCas9 mimics overexpression phenotypes in Arabidopsis.An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.CRISPR/Cas9 in allergic and immunologic diseases.Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.Error-Prone Repair of DNA Double-Strand Breaks.CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virusPrecision cancer mouse models through genome editing with CRISPR-Cas9.Conditional Control of CRISPR/Cas9 Function.Cystic Fibrosis Gene Therapy in the UK and Elsewhere.Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.Expression of CRISPR/Cas single guide RNAs using small tRNA promoters.A simple and efficient method to visualize and quantify the efficiency of chromosomal mutations from genome editingFunctional interrogation of non-coding DNA through CRISPR genome editing.GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases.Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeuticSynthetic CRISPR RNA-Cas9-guided genome editing in human cells
P2860
Q26748886-68BC66A9-7AAB-45CD-83AC-B8BF82C548B4Q26749278-A40BCC35-87CD-45B5-B29D-91C656DBEFB2Q26751344-7945A600-4625-470B-A2FB-A9700F073737Q26770012-57496C1F-BCB6-4996-A82A-481D89D0FAF6Q26775061-1F54CD4B-D640-4BB5-8B6B-86098B390A88Q26776515-240F0B65-AA46-4067-8751-DDE952B6256FQ26782747-B8A4F5DC-86F8-477F-88DC-9840E2C256DDQ26782876-55FAB31B-7FF7-438D-993C-655CEFB82928Q26784416-29BB5D82-4D87-40BE-B761-B9A130871479Q26787037-2209BBEA-3341-4305-A74A-55E5EFAB834AQ26799228-30D47E94-5557-4B57-9071-11579252A7F2Q26859390-D7B224C9-093C-45FB-B423-64B5896462C0Q28066273-5E761F71-5EAB-4FAB-A43E-0C05413658F4Q28066970-2C4525B3-125A-49B7-B7C6-6F90E7E1E3D6Q28066997-7753CA05-74FF-4AB6-8661-C260CAFFE184Q28076197-5BF56420-82D0-46A0-8D4D-30E847C3B187Q28076397-F61C2B02-C8FC-4FEC-B453-2A3B0A3D1FA2Q28081697-6016A323-94A2-43EE-A435-466492BE116EQ28085490-FB33FE3A-97E9-42C0-8056-24DB515200FEQ33652566-6953E04C-2F34-45A5-A1B2-5BA02D1BADC1Q33739733-1700CDFF-DC51-4A29-941A-4D66F32588B8Q33762815-A85CCA3C-5828-4FDE-A3F8-C3EA5E687019Q33786397-B38E3343-F9DC-42F8-8721-9866DA7F5A1BQ33806984-59A4F37E-62F3-459C-A01A-439595CDE7C7Q33850615-A702F393-8ED2-43E2-AD5A-9F73B7BEB150Q34046684-CFD4B4B0-A2F4-407E-94ED-13D575BF68F9Q34047460-1386E212-6F8F-45F8-A2A3-44DCD2A9DBB2Q34047618-2CC6C25B-5645-4730-8FAF-F2D56613FD6FQ34478858-5BE22B9F-6EFE-4D06-BFB7-528BA3F19AA0Q34478938-A515F53C-B279-4D33-8425-D97C281C7173Q34480103-430CE9E9-2444-49DA-A26E-0EF945ECBA44Q34519053-54F6B126-C10C-4B52-B06F-1197669D59EFQ35641704-274584D0-C81B-4D7A-8534-5AE3058EF506Q35871626-E2C51032-D244-49B0-A9B9-6D321D3659F7Q35952807-B707EE47-32CF-4192-9F9A-A9F7E17B27FBQ36164896-5961BAF1-F38E-4523-B341-22FA80D1F03CQ36306820-FC35E0EB-A230-45D1-80C1-50CF2EA1E3D6Q36372386-6F773174-D538-47FC-9A0D-01E63EAEB967Q36386251-F0A8C54E-BDCA-4BE0-8BB3-0716D2C08B65Q36419827-FE83D1EA-758E-438F-894B-31C87BE7C238
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Therapeutic genome editing: prospects and challenges
@ast
Therapeutic genome editing: prospects and challenges
@en
Therapeutic genome editing: prospects and challenges
@nl
type
label
Therapeutic genome editing: prospects and challenges
@ast
Therapeutic genome editing: prospects and challenges
@en
Therapeutic genome editing: prospects and challenges
@nl
prefLabel
Therapeutic genome editing: prospects and challenges
@ast
Therapeutic genome editing: prospects and challenges
@en
Therapeutic genome editing: prospects and challenges
@nl
P2860
P3181
P356
P1433
P1476
Therapeutic genome editing: prospects and challenges
@en
P2093
David Benjamin Turitz Cox
Feng Zhang
P2860
P2888
P304
P3181
P356
10.1038/NM.3793
P407
P577
2015-02-01T00:00:00Z